DaVita Inc (DVA)

Currency in USD
191.35
-3.47(-1.78%)
Closed·
191.350.00(0.00%)
·
DVA is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
188.75191.90
52 wk Range
101.00247.49
Key Statistics
Prev. Close
191.35
Open
189.63
Day's Range
188.75-191.9
52 wk Range
101-247.49
Volume
603.73K
Average Volume (3m)
727.14K
1-Year Change
54.7013%
Book Value / Share
-9.27
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DVA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
222.29
Upside
+16.17%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period

DaVita Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy

Analyst Ratings

3 Buy
4 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 222.29
(+16.17% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy228.00+19.15%220.00MaintainNov 02, 2026
UBS
Buy287.00+49.99%270.00MaintainNov 02, 2026
Barclays
Hold216.00+12.88%224.00MaintainNov 02, 2026
TD Cowen
Buy220.00+14.97%201.00UpgradeAug 07, 2026
Barclays
Hold224.00+17.06%218.00MaintainAug 05, 2026

DaVita Inc SWOT Analysis


Dialysis Dilemma
DaVita faces treatment volume challenges despite resilient business model, with cybersecurity incidents adding complexity to operational landscape
Financial Fortitude
Strong profitability and cash flow generation underscore DaVita's financial health, with analysts projecting EPS of $11.79 for FY 2025
Strategic Diversification
Explore DaVita's expanding Integrated Kidney Care segment and international operations, which offer growth potential amid core business headwinds
Market Valuation
With an average price target of $165, DaVita's stock trades near 52-week lows, potentially presenting value for investors amid industry challenges
Read full SWOT analysis

DaVita Inc Earnings Call Summary for Q3/2026

  • DaVita reported Q3 adjusted EPS of $3.82 on revenue of $3.58B, beating estimates of $3.55 and $3.51B respectively; stock fell 7.4% after-hours.
  • Full-year 2026 guidance narrowed to adjusted EPS of $14.30-$15.20; Integrated Kidney Care expected to generate at least $65M in adjusted operating income.
  • Management cited ongoing pressure from technology spending growing 20%+ annually and ACA-related commercial mix headwinds weighing on near-term margins.
  • CEO Rodriguez emphasized clinical investments improving outcomes; expanded HD dialyzer rollout expected to reach most patients by Nov 2026, benefits in late 2028.
  • Company projects 2027 volume growth above 2026 levels, pharmaceutical cost declines, but continued technology spending and reimbursement uncertainty remain risks.
Last Updated: 2026-10-29, 05:58 p/m
Read Full Transcript

Earnings

Latest Release
Oct 29, 2026
EPS / Forecast
3.82 / 3.55
Revenue / Forecast
3.58B / 3.51B
EPS Revisions
Last 90 days

DVA Income Statement

Compare DVA to Peers and Sector

Metrics to compare
DVA
Peers
Sector
Relationship
P/E Ratio
13.5x6.6x−0.2x
PEG Ratio
0.350.020.00
Price/Book
−20.4x5.3x2.6x
Price / LTM Sales
0.8x0.6x2.8x
Upside (Analyst Target)
16.2%357.2%65.6%
Fair Value Upside
Unlock11.5%10.0%Unlock

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
14.80M23.52%2.83B
Other Institutional Investors
44.34M70.46%8.48B
Public Companies & Retail Investors
3.79M6.02%724.48M
Total
62.92M100.00%12.04B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Berkshire Hathaway Inc.45.00%28,314,6665,418,011
BlackRock, Inc.3.91%2,460,987470,910

People Also Watch

308.67
VRSN
-1.09%
365.02
CB
-1.78%
244.97
NUE
-0.29%
505.67
MCO
-1.88%
106.13
GLW
+2.61%

FAQ

What Is the DaVita (DVA) Stock Price Today?

The DaVita stock price today is 191.35 USD.

What Stock Exchange Does DaVita Trade On?

DaVita is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for DaVita?

The stock symbol for DaVita is "DVA."

What Is the DaVita Market Cap?

As of today, DaVita market cap is 12.26B USD.

What Is DaVita's Earnings Per Share (TTM)?

The DaVita EPS (TTM) is 13.48.

When Is the Next DaVita Earnings Date?

DaVita will release its next earnings report on Feb 11, 2027.

From a Technical Analysis Perspective, Is DVA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has DaVita Stock Split?

DaVita has split 3 times.

How Many Employees Does DaVita Have?

DaVita has 78000 employees.

What is the current trading status of DaVita (DVA)?

As of Nov 07, 2026, DaVita (DVA) is trading at a price of 191.35 USD, with a previous close of 191.35 USD. The stock has fluctuated within a day range of 188.75 USD to 191.90 USD, while its 52-week range spans from 101.00 USD to 247.49 USD.

What Is DaVita (DVA) Price Target According to Analysts?

The average 12-month price target for DaVita is 222.29 USD, with a high estimate of 287 USD and a low estimate of 165 USD. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +16.17% Upside potential.

What Is the DVA Premarket Price?

DVA's last pre-market stock price is 192.80 USD. The pre-market share volume is 170.00, and the stock has decreased by -2.02, or -1.04%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.